日本女性医学学会は更年期障害から老年期の医学的諸問題まで思春期も含め女性の一生を通じ研究する医療従事者の団体です。

ORIGINAL Evaluation of skin condition by skin analyzer in adult women: Establishment of normal ranges for values of parameters of skin condition and effect of hormone replacement therapy on skin condition

Chikako YOSHIKAWA 1); 　Koji KOIKE1); Rena YAMAZAKI1); Sumiyo AKAZAWA-KUDOH2); Fumihide TAKANO3); Kouichi SUGIURA4); Taiichi KAKU5); Masaki INOUE1)
1) Department of Obstetrics and Gynecology, Graduate School of Medical Science, Kanazawa University
2) The 21st Century Multidisciplinary Medical Center, Lifestyle-related Disease Center , Kanazawa Medical University
3) Department of Pharmacognosy and Chemistry of Natural Products, School of Pharmacy and Pharmaceutical Sciences, Kanazawa University
4) Sugiura Clinic
5) Japan Bio Products Co., Ltd. Tokyo, Japan

<Summary>
A handy type of skin analyzer (Skin　Diagnosis　System　New　Aphrodete-III; SDSNA) is a convenient tool to evaluate skin conditions. We tested the reproducibility of SDSNA on the parameters of skin conditions, such as the quantity of sebum in the T-zone (midline of the glabellar) and water in the T-zone, U-zone (right cheek), and forearm, size of pores in the U-zone, and the width of the wrinkles below the eye, and confirmed that measurements of these parameters by SDSNA are quite reproducible with a coefficient of variation less than 15%. We also measured these parameters in a cross-section of 175 healthy adult women (20–79 years of age) and found that the quantity of sebum in the 40–60 age group, water in the forearm in people in their 60s, and the size of pores in people in their 60s were significantly decreased compared with people in their 20s with the width of the wrinkles significantly increased by age-specific changes compared with the 20s. We also investigated the effect of hormone replacement therapy (HRT) on skin condition in the 55–79 age group . HRT subject (N = 35) significantly increased the quantity of sebum, water, and the size of pores and decreased the width of wrinkles compared with normal subjects (N = 35). SDSNA is quite reproducible and a useful tool to evaluate skin conditions.

ORIGINAL Menopausal symptoms and hypothyroid dysfunction among perimenopause generation
Noriko Oi, MD1)2), Toshiko Kamo, MD, PhD2), Miyuki Katai, MD, PhD1)2) and Katsuhide Ohi, PhD3)
1) Department of gender-specific medicine, Tokyo Women’s Medical University East Medical center
2) Institute of Women’s Health, Tokyo Women’s Medical University
3) Institute of Advanced BioMedical Engineering and Science, Tokyo Women’s Medical University
<Summary>
Objective: To evaluate the prevalence of menopausal symptoms and its association with hypothyroid dysfunction.
Methods: This survey was applied from January through May 2010. The interviews were conducted on 174 patients who were 35-59 years old, when the patients made first-visit at our gender-specific medical department. The correlation of menopause-related 10 subjects which were listed on SMI was evaluated with thyroid function and menstrual status. Then, the prevalence data were analyzed circumstantially with JMP version 8.0.
Results: Sufficiency of parathyroid hormone had a significant correlation with menopausal complaint of “head ache” (p=0.0219). Furthermore, menopausal complaint of “hot flashes” had significant correlations with “sweat” and “head ache”.
Conclusion: Not only menopause generation but also menopause young women, even before the age of 40, have been affected by the menopausal symptoms and thyroid disorders.

 
ORIGINAL

The pattern of correlation between cardiometabolic and oxidative stress-related markers in premenopausal and postmenopausal subjects

Jui-Tung Chen (1) and Kazuhiko Kotani (2)

1) Jui-Tung Chen Clinic, Tokyo, Japan
2) Department of Clinical Laboratory Medicine / Department of Public Health, Jichi Medical University, Tochigi, Japan

ABSTRACT Background: It may be a key factor of women’s health to elucidate the pattern of correlation between cardiometabolic and oxidative stress-related markers in potential roles of menopause.
Objectives: The objective of this study was to compare the correlation pattern in apparently healthy premenopausal and postmenopausal women.
Methods: Blood oxidative stress levels were determined in 143 women (72 premenopaue and 71 women 5 years after menopause) using a Diacron-reactive oxygen metabolites (d-ROMs) test and a biological anti-oxidant potential (BAP) test. Body mass index, blood pressure, white blood cell counts, serum lipids, hemoglobin A1c and high sensitivity C-reactive protein were also determined.
Results: The d-ROMs and BAP levels were not significantly different in the premenopausal and postmenopausal subjects. In the adjusted analysis on premenopausal subjects, d-ROMs showed a significant positive correlation with white blood cell counts and high sensitivity C-reactive protein. In the adjusted analysis on postmenopausal subjects, BAP was significantly and inversely correlated with low-density lipoprotein cholesterol.
Conclusions: These data suggested that the correlation patterns of cardiometabolic markers with oxidative stress status can be different in association with menopause.

 
ORIGINAL Long-Term (52-week) Efficacy and Safety of an Estradiol Gel (Divigel® 1mg) in Patients with Climacteric Disturbance and Estrogen Deficiency Syndrome

Hiroaki OHTA 1)＊; Masahiro NOZAKI 2)＊; Hideki MIZUNUMA 3)＊＊
Yuji TAKETANI 4)＊;
1) Clinical Medical Research Center, International University of health and welfare．Women's Medical Center of Sanno Medical Center
2) Nozaki Women’s Clinic
3) Department of Obstetrics and Gynecology, University of Hirosaki
4) Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tokyo
＊ Medical Expert, ＊＊ Coordinating Investigator

Summary
A 52-week, multi-center, open-label phase-III, long-term clinical study was conducted in 98 patients to assess the safety and efficacy of Divigel® 1 mg, a gel formulation containing estradiol, for the treatment of patients with climacteric disturbance and ovarian deficiency. For patients with intact uterus, 2.5 to 5.0 mg of medroxyprogesterone acetate was administered in combination with Divigel® 1 mg during the treatment period.
As for clinical findings on safety, skin irritation at the local application site was observed in 24 of the 98 patients (24.5%), and the irritation level was mild except in one patient who reported moderate irritation, with no worsening of symptom severity over the duration of treatment. Other adverse events were similar in severity and frequency to those reported for conventional hormonal therapy and no tendency specific to Divigel® 1 mg was observed. These findings suggest Divigel® 1 mg presents no particular issues in its long-term clinical application.
In terms of clinical findings on efficacy, moderate to marked improvements in vasomotor symptoms (hot flushes) was observed in 82.5% of the evaluable patients receiving long-term Divigel, with this improvement maintained over the entire 52 weeks. In addition, improvements were also seen with Divigel in subjective symptoms, which included perspiration, neuropsychiatric symptoms, sleep disorder, and symptoms associated with vaginal atrophy.
These study results show that there are no safety issues associated with　long-term treatment with Divigel® 1 mg, and suggest that Divigel® 1 mg will be useful for treatment of symptoms associated with menopausal syndrome, which include neuropsychiatric symptoms, sleep disorder and vaginal atrophy, in addition to perspiration and hot flushes.